Vestmark Advisory Solutions Inc. Has $7.67 Million Holdings in CRISPR Therapeutics AG $CRSP

Key Points

• Vestmark Advisory Solutions Inc. has reduced its position in CRISPR Therapeutics AG by 7.7%, now holding approximately 0.26% of the company, valued at $7.67 million.
• Director Simeon George significantly increased his ownership by purchasing 989,812 shares for about $51.5 million, representing a 133.69% increase in his position.
• CRISPR Therapeutics reported earnings per share of ($1.29), surpassing analysts' estimates, but had revenues of only $0.89 million, compared to an expectation of $6.44 million.

Vestmark Advisory Solutions Inc. decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 7.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 225,306 shares of the company's stock after selling 18,728 shares during the quarter. Vestmark Advisory Solutions Inc. owned approximately 0.26% of CRISPR Therapeutics worth $7,667,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Costello Asset Management INC purchased a new position in shares of CRISPR Therapeutics during the 1st quarter valued at $27,000. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics during the fourth quarter valued at $30,000. Ameriflex Group Inc. purchased a new position in CRISPR Therapeutics in the fourth quarter valued at about $36,000. NBC Securities Inc. grew its stake in CRISPR Therapeutics by 156,300.0% in the first quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock valued at $53,000 after purchasing an additional 1,563 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in CRISPR Therapeutics in the 4th quarter worth about $71,000. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George acquired 989,812 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The stock was acquired at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the transaction, the director owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Naimish Patel sold 3,932 shares of the stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider owned 6,068 shares of the company's stock, valued at approximately $218,083.92. The trade was a 39.32% decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on CRSP shares. Barclays boosted their price target on CRISPR Therapeutics from $42.00 to $56.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Piper Sandler restated an "overweight" rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Bank of America cut their price target on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, Royal Bank Of Canada upped their price objective on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a "sector perform" rating in a report on Tuesday, August 5th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $71.60.

CRISPR Therapeutics Stock Down 2.0%

Shares of NASDAQ:CRSP traded down $1.09 during trading on Wednesday, reaching $53.07. The stock had a trading volume of 2,001,316 shares, compared to its average volume of 3,172,679. The stock has a fifty day simple moving average of $54.26 and a two-hundred day simple moving average of $44.69. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of -9.77 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. The business had revenue of $0.89 million during the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics's quarterly revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.49) EPS. On average, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.